Literature DB >> 20695744

Management of Helicobacter pylori infection.

Francesco Costa1, Mario M D'Elios.   

Abstract

Helicobacter pylori is the cause of peptic ulcer, gastric cancer and gastric lymphoma. Diagnosis of H. pylori infection can be made using invasive and noninvasive tests. Invasive tests based on endoscopy, such as histology, are recommended when a gastric malignancy is suspected. Alternatively, noninvasive tests, such as the urea breath test and stool tests are useful for H. pylori diagnosis and follow-up. Triple therapy with either amoxicillin or metronidazole, clarithromycin and proton pump inhibitor given twice daily for 7-14 days is the recommended first-line treatment, after having checked the individual clarithromycin antimicrobial susceptibility. A triple therapy with levofloxacin, amoxicillin and proton pump inhibitor for 10-14 days should be used as second-line treatment, where the strains are susceptible to fluoroquinolone. Alternatively, bismuth-based quadruple therapy is recommended.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20695744     DOI: 10.1586/eri.10.75

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  3 in total

1.  Helicobacter pylori management in primary care.

Authors:  Mario M D'Elios; Elena Silvestri; Giacomo Emmi; Aija Zilevica; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2011-09-22       Impact factor: 3.397

2.  Helicobacter pylori neutrophil activating protein as target for new drugs against H. pylori inflammation.

Authors:  Theodora Choli-Papadopoulou; Filippos Kottakis; Georgios Papadopoulos; Stefanos Pendas
Journal:  World J Gastroenterol       Date:  2011-06-07       Impact factor: 5.742

3.  Genotypic and phenotypic variation of Lewis antigen expression in geographically diverse Helicobacter pylori isolates.

Authors:  Mary Ann Pohl; William Zhang; Sunny N Shah; Edgardo L Sanabria-Valentín; Guillermo I Perez-Perez; Martin J Blaser
Journal:  Helicobacter       Date:  2011-12       Impact factor: 5.753

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.